Cozaar, also known as losartan, is an oral treatment for high blood pressure (hypertension), also known as angina. It belongs to the angiotensin-converting enzyme (ACE) inhibitors class of medicines. Hypertension is a hormonal disorder characterized by high blood pressure that leads to heart failure, stroke, and, in some cases, heart attack.
The global market for Cozaar, which includes Angiotensin-II receptor blockers (barotanezin, losartan), is experiencing steady growth. As of 2023, the global market size was USD 109.6 million.
Research and reviewer
10COZAAR tablets
9 million people take COZAAR every day. Its effectiveness and low risk of side effects make it a preferred choice for many patients. COZAAR tablets are available in various forms, including tablets, patches, and oral jelly. For instance, COZAAR tablets are available in wafers and also in blister packs. COZAAR is approved for the treatment of high blood pressure (hypertension) in adults and children. It is also approved for the treatment of angina (chest pain) in adults and children. The approved uses of COZAAR are hypertension (hypertension), angina pectoris (chest pain), and congestive heart failure (COX-2 inhibitor).
The growth of the market is supported by rising health awareness and expanding healthcare infrastructure. Increased awareness about cardiovascular health and the development of alternative treatments support market growth.
Increased healthcare spending, especially in emerging economies, are key factors driving the growth of the market. Countries such as China and India are driving market growth due to increased healthcare spending. China is also a key player in the Cozaar market. India has the world leading prevalence of hypertension, contributing to its drive in healthcare demand. India's healthcare infrastructure, including that of its people, is expanding rapidly. India's rising healthcare expenditure, particularly in emerging economies, support market growth.
Despite its growth, the market is not without restraints. Variations in dosage, availability, and cost may impact supply chain and in turn, the market faces challenges such as cost-liamliness and recalls. Excluding convenience and accessibility issues, the market size is expected to grow at a compound annual growth rate (CAGR) of 5.2% during 2024.
Asia-Pacific is experiencing moderate growth driven by increasing healthcare expenditure, which is boosting adoption of angiotensin-II type 1 (angiotensin II) receptor blockers (barotanezin, losartan), as a first-line therapy. This expansion is expected to be further driven by the increasing geriatric population in countries such as Australia, New Zealand, and South Korea. The growing awareness about cardiovascular health and the expanding healthcare infrastructure are also contributing to the growth of the market.
The market is segmented based on product type, applications, and regions.
The market is segmented into anti-hypertensive, anti-angina, and.
Dr. hypericum Pharmaceuticals, a renowned company, is one of the leading players in the Cozaar market. It is a subsidiary of Dr. GSK, a major player in the angiotensin II receptor blockers class of medicines. hypericum is a multinational pharmaceutical company that is involved in developing and delivering over-the-counter and prescription medicines for patients across North America, Europe, the Middle East, and the USA.
There is also a significant presence of over-the-counter medicines like COX-2 inhibitors in the market. COZAR markets the tablet, gel, and oral jelly to a large extent. The patent for COZAR is valid until 2025.
Several other companies are major players in the market, including Abbott, Boehringer-Sooncom, Dr. Reddy's Laboratories, Lupin Healthcare, Sun Pharmaceutical Industries Ltd., Mylan, and others.
Medicationinclude:
– Cozaar for high blood pressure, heart failure, angina, heart failure, dyspepsia, angina pectoris, angina pectoris pectoris or pharyngitis. – Angiotensin converting enzyme (ACE) Inhibitors and Diuretics – Angiotensin II Inhibitors and Diuretics – Diuretics – Angiotensin receptor blockers – Diuretics – ACE Inhibitors and angiotensin II Inhibitors – Angiotensin receptor blockers.
Cozaar is an ACE inhibitor which blocks the effects of angiotensin II and angiotensin I, two angiotensin receptor blockers.
Angiotensin II Inhibitors (eg, angiotensin receptor blockers, ACE Inhibitors) and Angiotensin receptor blockers do not have any impact on blood pressure in patients with hypertension. The only difference between these medications is the dose and duration of therapy.
Cozaar takes about one week to start working and continues to be effective for several weeks after your dose is taken. The effects of Cozaar may be temporary, but it should be discussed with your healthcare provider. Do not stop taking Cozaar without first consulting your doctor.
No, Cozaar is not effective for everyone. You may not be prescribed Cozaar but your healthcare provider may prescribe it for you.
Cozaar is usually taken daily and is available with a prescription from your healthcare provider. You may use it for short-term treatment of high blood pressure. Your doctor may also recommend a lower-dose or higher-dose regimen that is taken long-term.
What should I do if I miss a dose?
If you miss a dose of Cozaar and you still feel well, you should take the next dose as soon as you remember. Do not take a double dose.
What if I overdose?
If you think you may be having an overdose, you may be prescribed a different medication, such as or lisinopril. You should seek emergency medical attention right away if you experience signs of an overdose, such as severe drowsiness, nausea, or loss of consciousness.
What are the possible side effects?
Some of the common side effects of Cozaar include:
What other drugs should I avoid?
It is important that you discuss your medication with your healthcare provider before starting or continuing any new medications. They can help you decide if Cozaar is right for you.
Store Cozaar at room temperature away from light and moisture. Keep Cozaar out of the reach of children.
Cozaar may cause side effects, but most of the side effects are mild.
Cozaar (losartan) is used to treat high blood pressure (hypertension), reduce the swelling of the legs, and treat other heart conditions (angina, heart failure, and other forms of high blood pressure).
The common side effects of Cozaar (losartan) can include the swelling of your legs, ankles, or feet. These side effects may last for a few days or even weeks after you stop taking Cozaar. Tell your doctor if any of these side effects persist or get worse. This medicine may be dangerous to have no side effects.
Before taking Cozaar (losartan), tell your doctor about all of your medical conditions, including if you:
The recommended starting dose of Cozaar is 2.5 mg once daily, taken at the same time each day. The dose may be increased to 5 mg once daily at any time during your treatment.
Cozaarim is used for the treatment of advanced HIV infection (as an partial or partial); as an combination drug and as an HIV prophylactic. Cozaarim is also used in combination with other antiretroviral medications, AIDS and HIV PrEP. It can be used to treat certain forms of fungal infections, such as certain skin infections, including sun-ETHODS: Cozaarim is used to treat: fungal infections of the skin and soft tissue of the scalp (including skinfibrosis), including infected or recanning fungal infections of the skin and soft tissue caused by fungi. This medicine will help to reduce the severity of the infection and the risk of the recurrence. Using Cozaarim in combination with these drugs will decrease the risk of a recurrence of fungal infections. It will also help to reduce the risk of sunburn and scalp infections. These measures will decrease the severity of the infection and the risk of the recurrence. DURAL/INGREDIENTS: Each mL of Cozaarim is crushed and dissolved in water. The contents of one mL of oral Cozaarim are suspended in 100 mL of water and stored at 4°C. Cozaarim (Cozaar) is indicated for use in the treatment of advanced HIV infection (as an partial or partial) and as an HIV prophylactic. It is also indicated for treatment of fungal infections of the skin and soft tissue caused by fungi. It is also indicated for the treatment of sunburn and scalp infections. It is indicated for treatment of systemic fungal infections at a dose of 100 mg/m2 or 200 mg/m2. DIFFERENTIAL ingredients: Cozaarim (Cozaarim) is a lipase inhibitor. Cozaarim has not been evaluated for use in children under 12 years of age. Inhibition of lipase leads to inhibition of the clearance of amylin and aspirin. Inhibitoring the lipase process can decrease the amount of amylin produced by the liver. The effect of Cozaarim is not known. Injection: In the clinical use, a single oral dose (2 mL) of Cozaarim (Cozaarim) is injected into the body. The usual starting dose is 200 mg. The recommended starting dose in the treatment of advanced HIV infection is 50 mg/m2. The recommended starting dose in the treatment of fungal infections of the scalp and the nails is 100 mg/m2. The dose of Cozaarim is 200 mg/m2 or 400 mg/m2. The dose of Cozaarim in the treatment of systemic fungal infections at a dose of 100 mg/m2 or 200 mg/m2. The recommended starting dose in the treatment of systemic fungal infections at a dose of 100 mg/m2 or 200 mg/m2. The recommended starting dose in the treatment of fungal infections of the skin and soft tissue caused by fungi. The contents of one mL of Cozaarim are suspended in 100 mL of water and stored at 4°C. It is indicated for the treatment of systemic fungal infections at a dose of 100 mg/m2 or 200 mg/m2. Cozaarim should be used with caution in patients with a known sensitivity to cozaarim to sunburn and to systemic fungal infections at a dose of 100 mg/m2 or 200 mg/m2.
Stade de France Pharmacy